Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - arsenic
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp0765874a313ce115023e01847b82b59e
identifier: http://ema.europa.eu/identifier
/EU/1/20/1427/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Arsenic trioxide Mylan 1 mg/ml concentrate for solution for infusion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-0765874a313ce115023e01847b82b59e
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/20/1427/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - arsenic
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Arsenic trioxide Mylan is used in adult patients with newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL), and in adult patients, whose disease has not responded to other therapies. APL is a unique type of myeloid leukaemia, a disease in which abnormal white blood cells and abnormal bleeding and bruising occur.
Arsenic trioxide Mylan must be given under the supervision of a physician experienced in the treatment of acute leukaemias.
You must not receive Arsenic trioxide Mylan If you are allergic to arsenic trioxide or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
You must talk to your doctor or nurse before you are given Arsenic trioxide Mylan, if
Your doctor will take the following precautions:
Tests will be performed to check the amount of potassium, magnesium, calcium and creatinine in your blood before your first dose of Arsenic trioxide Mylan.
You should have an electrical recording of the heart (electrocardiogram ECG) performed before your first dose.
Blood tests (potassium, magnesium, calcium, liver function) should be repeated during your treatment with Arsenic trioxide Mylan.
In addition, you will receive electrocardiograms twice weekly.
If you are at risk for a certain type of abnormal heart rhythm (e.g. torsade de pointes or QTc prolongation), your heart will be monitored continuously.
Your doctor may monitor your health during and after treatment, since arsenic trioxide, the active substance in Arsenic trioxide Mylan, may cause other cancers. You should report any new and exceptional symptoms and circumstances whenever you see your doctor.
Follow-up of your cognitive and mobility functions if you are at risk for vitamin B1 deficiency.
Children and adolescents
Arsenic trioxide Mylan is not recommended in children and adolescents below 18 years of age.
Other medicines and Arsenic trioxide Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
In particular tell your doctor
Arsenic trioxide Mylan with food and drink
There are no restrictions on your food or drink while you are receiving Arsenic trioxide Mylan.
Pregnancy
Ask your doctor or pharmacist for advice before taking any medicine.
Arsenic trioxide Mylan may cause harm to the foetus when used by pregnant women.
If you are able to become pregnant, you must use effective birth control during treatment with Arsenic trioxide Mylan and for 6 months following completion of treatment.
If you are pregnant or you become pregnant during the treatment with Arsenic trioxide Mylan, you must ask your doctor for advice.
Men should also use effective contraception and be advised to not father a child while receiving Arsenic trioxide Mylan and for 3 months following completion of treatment.
Breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine.
The arsenic in Arsenic trioxide Mylan passes into breast milk.
Because Arsenic trioxide Mylan can harm nursing infants, do not breast-feed while on and until two weeks after the last dose of Arsenic trioxide Mylan.
Driving and using machines
Arsenic trioxide Mylan is expected to have no or negligible influence on your ability to drive and use machines.
If you experience discomfort or if you feel unwell after a Arsenic trioxide Mylan injection, you should wait until the symptoms go away before driving or using machines.
Arsenic trioxide Mylan contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially sodium-free .
Duration and frequency of treatment
Patients with newly diagnosed acute promyelocytic leukaemia
Your doctor will give you Arsenic trioxide Mylan once every day as an infusion. In your first treatment cycle, you may be treated every day up to 60 days at most or until your doctor determines that your disease is better. If your disease responds to Arsenic trioxide Mylan, you will be given 4 additional treatment cycles. Each cycle consists of 20 doses given 5 days per week (followed by 2 days interruption) for 4 weeks followed by 4 weeks interruption. Your doctor will decide exactly how long you must continue on therapy with Arsenic trioxide Mylan.
Patients with acute promyelocytic leukaemia, whose disease has not responded to other therapies
Your doctor will give you Arsenic trioxide Mylan once every day as an infusion. In your first treatment cycle, you may be treated every day up to 50 days at most or until your doctor determines that your disease is better. If your disease responds to Arsenic trioxide Mylan, you will be given a second treatment cycle of 25 doses given 5 days per week (followed by 2 days interruption) for 5 weeks. Your doctor will decide exactly how long you must continue on therapy with Arsenic trioxide Mylan.
Method and route of administration
Arsenic trioxide Mylan must be diluted with a solution containing glucose or a solution containing sodium chloride.
Arsenic trioxide Mylan is normally given by a doctor or a nurse. It is given as a drip (infusion) into a vein over 1-2 hours, but the infusion may last longer if side effects like flushing and dizziness occur.
Arsenic trioxide Mylan must not be mixed with or infused through the same tube with other medicines.
If your doctor or nurse gives you more Arsenic trioxide Mylan than he/she should
You may experience convulsions, muscle weakness and confusion. If this happens, treatment with Arsenic trioxide Mylan must be stopped immediately and your doctor will treat the arsenic overdose.
If you have any further question on the use of this medicine, ask your doctor or pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse straight away if you notice the following side effects, as these may be signs of a severe condition called differentiation syndrome , which might be fatal:
Tell your doctor or nurse straight away if you notice one or more of the following side effects, as these may be signs of allergic reaction:
While on treatment with Arsenic trioxide Mylan, you may experience some of the following reactions:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Not known (frequency cannot be estimated from the available data):
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial label and the carton.
Do not freeze.
After dilution, if not used immediately, storage times and conditions before use are the responsibility of your doctor and would normally not be longer than 24 hours at 2 C 8 C, unless dilution has taken place in a sterile environment.
This medicine must not be used if you notice foreign particulate matter or if the solution is discoloured.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Arsenic trioxide Mylan contains
What Arsenic trioxide Mylan looks like and contents of the pack Arsenic trioxide Mylan is a concentrate for solution for infusion (sterile concentrate). It is supplied in glass vials as a concentrated, clear, colourless, aqueous solution. Each carton contains 1 or single-use glass vials.
Marketing Authorisation Holder
Mylan Ireland Limited Unit 35/36 grange Parade Baldoyle Industrial Estate Dublin Ireland
Manufacturer Haupt Pharma Wolfratshausen GmbH Pfaffenrieder Stra e 5 82515 Wolfratshausen Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Mylan bvba/sprl T l/Tel: + 32 (0)2 658 61 Lietuva Mylan Healthcare UAB
Tel: +370 5 205 1
: +359 2 44 55 Luxembourg/Luxemburg Mylan bvba/sprl T l/Tel: + 32 (0)2 658 61 (Belgique/Belgien)
esk republika Viatris CZ s.r.o. Tel: + 420 222 004 Magyarorsz g Mylan EPD Kft. Tel: + 36 1 465 2Danmark Viatris ApS Tlf: +45 28 11 69 Malta V.J. Salomone Pharma Ltd Tel: + 356 21 22 01 Deutschland Viatris Healthcare GmbH Tel: + 49- 800 0700 Nederland Mylan BV Tel: +31 (0)20 426 3Eesti BGP Products Switzerland GmbH Eesti filiaal
Tel: + 372 6363 Norge Viatris AS Tlf: + 47 66 75 33
Generics Pharma Hellas
: +30 210 993 6 sterreich Arcana Arzneimittel GmbH Tel: +43 1 416 2Espa a Viatris Pharmaceuticals, S.L.U. Tel: + 34 900 102 Polska Mylan Healthcare Sp. z o.o. Tel: + 48 22 546 64 France Viatris Sant
T l: +33 4 37 25 75 Portugal Mylan, Lda. Tel: + 351 214 127 Hrvatska Viatris Hrvatska d.o.o. Tel: +385 1 23 50 Rom nia BGP Products SRL Tel: +40 372 579 Ireland Mylan Ireland Limited Tel: +353 1 8711Slovenija Viatris d.o.o. Tel: + 386 1 23 63 sland Icepharma hf. S mi: +354 540 8Slovensk republika Viatris Slovakia s.r.o.
Tel: +421 2 32 199 Italia Mylan Italia S.r.l. Tel: + 39 02 612 46Suomi/Finland Viatris Oy Puh/Tel: +358 20 720 9
Varnavas Hadjipanayis Ltd : +357 2220 7Sverige Viatris AB
Tel: +46 (0) 8 630 19 Latvija Mylan Healthcare SIA
Tel: +371 676 055 United Kingdom (Northern Ireland) Mylan IRE Healthcare Limited Tel: +353 18711This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-0765874a313ce115023e01847b82b59e
Resource Composition:
Generated Narrative: Composition composition-en-0765874a313ce115023e01847b82b59e
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1427/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - arsenic
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp0765874a313ce115023e01847b82b59e
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp0765874a313ce115023e01847b82b59e
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1427/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Arsenic trioxide Mylan 1 mg/ml concentrate for solution for infusion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en